A biomimetic lipoprotein delivers nerve growth factor in experimental brain injury

Professor Junfeng Feng’s team at Renji Hospital Neurosurgery, Shanghai Jiao Tong University School of Medicine, recently published “Neurophilic Biomimetic Lipoprotein-Mediated Targeted Nerve Growth Factor Delivery for Traumatic Brain Injury Therapy” online in Advanced Science (Chinese Academy of Sciences category 1; impact factor 14.1). The researchers developed the neurophilic biomimetic lipoprotein Nc-rHDL@P for efficient brain-targeted nerve growth factor (NGF) delivery, improving neurological function after TBI in the experiments. This offers a research strategy for TBI and other neurological diseases.

TBI is a leading cause of death and disability worldwide. Effective clinical medicines promoting neural repair after TBI are lacking. NGF, an important neurotrophic factor, can promote neural cell survival, growth and differentiation, but poor blood–brain barrier (BBB) penetration and inadequate targeting limit its clinical use.

The team designed a biomimetic core–shell lipoprotein. Hyaluronic acid and protamine in the core mimic a cellular matrix to protect NGF activity; an ApoE3-reconstituted high-density lipoprotein (rHDL) shell enhances BBB penetration; and surface αRDP, a neuron-affinity peptide derived from rabies virus glycoprotein, provides neuronal targeting. In vitro BBB and controlled cortical impact (CCI) mouse models showed efficient barrier penetration and accumulation around neurons on the injured side. In vitro pharmacodynamic experiments showed improved survival of injured neurons and promoted neurite growth and differentiation in PC12 cells, human neural stem cells and Schwann cells.
The study then evaluated treatment in CCI mice. Brain inflammation and glial scars impede repair. Nc-rHDL@P significantly reduced astrocyte and microglial activation and proinflammatory factor expression. It also promoted neuronal survival and regeneration: cortical and hippocampal neuronal survival, dendritic spine density and newborn neuron numbers increased. Treated CCI mice performed significantly better than controls on sensorimotor and spatial memory tests.
The neurophilic biomimetic nanodelivery system achieved targeted NGF delivery, opening a research route for neuroprotection after TBI and providing an approach for other neurotrophic factors.
Director Junfeng Feng is corresponding author. Assistant researcher Jialin Huang, doctoral student Wenye Wang, master’s student Yidong Peng, physician Weiji Weng and doctoral student Hanyu Wei are co-first authors. Jiyao Jiang, Renji Chief Expert and Shanghai Institute of Head Trauma Director, and Xiaoling Gao of Pharmacology and Chemical Biology at the School of Basic Medical Sciences, Shanghai Jiao Tong University School of Medicine, provided important guidance.
Corresponding author

Junfeng Feng — Chief Physician
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Chief physician, research professor and doctoral supervisor; Director of Renji Neurosurgery; Deputy Director of the Shanghai Institute of Head Trauma; member of a working group of the Chinese Medical Association’s Trauma Society; deputy head of the trauma working group of the Shanghai Medical Association’s Neurosurgery Society; committee member and secretary of the Shanghai Medical Doctor Association’s Neurosurgery Division.
His honours include the Wang Zhongcheng Chinese Young Neurosurgeon Award, the Innovation Award of the Wang Zhengguo Trauma Medicine Award, the Shanghai Silver Snake Award, Shanghai Outstanding Academic Leader (Young) and Shanghai Outstanding Young Medical Talent, and the inaugural National Outstanding Young Physician designation in the high-level medical talent programme.
He focuses on clinical surgery and comprehensive treatment for TBI and neurocritical illness, and studies brain protection and neural repair and regeneration. He has received five National Natural Science Foundation grants, holds 20 granted patents and has published over 30 SCI-indexed papers.
Professor Junfeng Feng
First authors

Jialin Huang — Assistant Researcher, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Master’s and doctoral degrees from Shanghai Jiao Tong University School of Medicine. Focuses on brain-targeted delivery systems and brain diseases; supported by an NSFC Young Scientists grant and the Shanghai Sailing Programme for Young Science and Technology Talent. As first or co-first author, she has published 11 SCI-indexed papers in Advanced Materials, Advanced Science, Advanced Functional Materials, Journal of Nanobiotechnology, Cell Death and Differentiation, ACS Applied Materials & Interfaces and Nature Communications, with combined impact factors of 131. She holds three granted invention patents.

Wenye Wang — Graduate Student, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Enrolled in the eight-year clinical medicine programme. Over the preceding five years, he published one SCI-indexed paper as co-first author in Advanced Science, with an impact factor of 14.1.

Yidong Peng — Master’s Student, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Master’s degree from Shanghai Jiao Tong University School of Medicine and doctoral studies at Zhejiang University School of Medicine. Over the preceding five years, he published two SCI-indexed papers as co-first author in Journal of Nanobiotechnology and Advanced Science, with combined impact factors of 26. He holds one granted invention patent.

Weiji Weng — Resident Physician
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Doctorate and postdoctoral training at Shanghai Jiao Tong University. His clinical focus is brain injury and neurocritical care, including emergency treatment of severe TBI, cerebral haemorrhage and large cerebral infarction, and individualised treatment of hydrocephalus, subdural haematoma and cranial defects.
Supported by an NSFC Young Scientists grant. Over the preceding five years, he published 11 SCI-indexed papers as first, co-first or co-corresponding author in Nature Communications, Cell Death and Differentiation, Advanced Science and other journals, with combined impact factors of 128. He holds two granted invention patents and has completed three research-result translation projects.
Weiji Weng — Resident Physician

Hanyu Wei — Doctoral Student, Renji Hospital, Shanghai Jiao Tong University School of Medicine
Enrolled in the 2020 cohort of the eight-year clinical medicine programme. Over the preceding five years, he published one SCI-indexed paper as co-first author in Advanced Science, with an impact factor of 14.1.
Copyright notice: Intellectual property in content published by BrainMed’s Neurosurgery News, Neurointerventional News, Brain Medical Consultation and AiBrain belongs to BrainMed, the organisers, original authors and other rights holders. Republishing, excerpting, copying, cropping or recording without permission is prohibited. Authorised use must acknowledge the source. Forwarding and sharing are welcomed.
近日,上海交通大学医学院附属仁济医院神经外科冯军峰教授团队在国际知名期刊《Advanced Science》(中科院一区,IF 14.1)在线发表了题为“Neurophilic Biomimetic Lipoprotein-Mediated Targeted Nerve Growth Factor Delivery for Traumatic Brain Injury Therapy”的研究成果。该研究成功开发出一种“嗜神经性仿生脂蛋白”(Nc-rHDL@P),实现了对神经生长因子(NGF)的高效脑靶向递送,显著改善创伤性脑损伤(TBI)后的神经功能。这一成果为TBI及其他神经系统疾病的治疗提供了新策略。

TBI是全球范围内导致死亡及残疾的主要原因之一,目前临床上缺乏有效的促进TBI后神经修复的药物。NGF作为神经营养因子家族的重要成员,具有促进神经细胞存活、生长和分化的潜力,但其临床应用受限于血脑屏障(BBB)穿透性差和靶向性不足等问题。

嗜神经性仿生脂蛋白的构建及其作用机制
研究团队通过仿生设计,构建了仿生核壳结构的脂蛋白载体:以透明质酸和鱼精蛋白为核心辅料模拟类细胞基质保护NGF的生物活性;以ApoE3重构的高密度脂蛋白(rHDL)外壳增强BBB穿透能力;表面修饰源自狂犬病毒糖蛋白的神经亲和肽(αRDP)赋予其神经元靶向性。体外BBB模型及控制性皮层损伤(CCI)小鼠模型表明,Nc-rHDL@P高效穿透BBB并富集于脑损伤侧神经元周围。体外药效学研究显示Nc-rHDL@P显著提升了受损神经元的存活率,并促进PC12细胞、人神经干细胞和雪旺细胞的神经突生长与分化。
进而,该研究系统评估了Nc-rHDL@P对CCI小鼠的治疗效果。脑内炎症反应和胶质瘢痕形成是阻碍TBI后神经修复的关键因素。研究发现,Nc-rHDL@P治疗可显著减少星形胶质细胞和小胶质细胞的激活,降低促炎因子表达。更重要的是,Nc-rHDL@P显著促进了神经元存活和神经再生。在CCI小鼠中,该治疗显著改善皮层和海马区的神经元存活率,并显著提升了树突棘密度和新生神经元数量。在行为学测试中,接受Nc-rHDL@P治疗的CCI小鼠在感觉运动功能和空间记忆能力方面均显著优于对照组。
该研究成功构建具有嗜神经性的仿生纳米递送系统,实现NGF的精准脑靶向递释。这不仅为TBI的神经保护治疗开辟新路径,也为其他神经营养因子的靶向递送提供了新思路。
上海交通大学医学院附属仁济医院神经外科主任冯军峰教授为通讯作者,黄佳琳助理研究员、王文烨博士研究生、彭亦东硕士研究生、翁维吉医师、魏涵宇博士研究生为本研究的共同第一作者,仁济医院首席专家、上海市颅脑创伤研究所所长江基尧教授和上海交通大学医学院基础医学院药理学与化学生物学系高小玲教授为本研究提供了重要指导。
通讯作者简介

冯军峰 主任医师
上海交通大学医学院附属仁济医院
主任医师、研究员、博士研究生导师
上海交通大学医学院附属仁济医院神经外科主任
上海市颅脑创伤研究所副所长
中华医学会创伤学分会学组委员
上海市医学会神经外科分会创伤学组副组长
上海市医师协会神经外科分会委员兼秘书
获王忠诚中国神经外科青年医师奖、王正国创伤医学奖创新奖、上海市银蛇奖、上海市优秀学术带头人(青年)、上海市杰出青年医学人才、第一届医学高层次人才“国家优秀青年医师”
专注于颅脑创伤、神经重症相关临床手术及综合救治,开展脑损伤保护和神经修复再生研究。获国家自然科学基金5项、授权专利20项、发表30余篇SCI论文
冯军峰 教授
第一作者简介

黄佳琳 助理研究员
上海交通大学医学院附属仁济医院
上海交通大学医学院硕士、博士
专注于脑靶向递送系统的构建及脑疾病研究
获得国家自然科学基金青年项目、上海市青年科技英才扬帆计划支持
以第一或共同第一作者在Advanced Materials、Advanced Science、Advanced functional materials、Journal of nanobiotechnology, Cell Death and Differentiation、ACS Applied Materials & Interfaces、Nature Communications等SCI杂志发表论文多篇11篇,累计影响因子131分
授权发明专利3项

王文烨 研究生
上海交通大学医学院附属仁济医院
上海交通大学医学院临床医学八年制在读
近五年以共同第一作者在Advanced Science等SCI杂志发表论文1篇,累计影响因子14.1分

彭亦东 硕士研究生
上海交通大学医学院附属仁济医院
上海交通大学医学院硕士、浙江大学医学院博士在读
近五年以共同第一作者在Journal of Nanobiotechnology、Advanced Science发表SCI论文2篇,累计影响因子26分
授权发明专利1项

翁维吉 住院医师
上海交通大学医学院附属仁济医院
上海交通大学医学院博士、博士后
专注于颅脑损伤和神经危重症的救治,包括对重型脑外伤、脑出血、大面积脑梗的急救和对脑积水、硬膜下血肿、颅骨缺损的个体化治疗
获得国家自然科学基金青年项目支持
近五年以第一、共同第一或共同通讯作者在Nature Communications、Cell Death and Differentiation、Advanced Science等SCI杂志发表论文11篇,累计影响因子128分
授权发明专利2项,实现科技成果转化3项
翁维吉 住院医师

魏涵宇 博士研究生
上海交通大学医学院附属仁济医院
上海交通大学医学院2020级临床医学八年制博士在读
近五年以共同第一作者在Advanced Science等SCI杂志发表论文1篇,累计影响因子14.1分
声明:脑医汇旗下神外资讯、神介资讯、脑医咨询、AiBrain所发表内容之知识产权为脑医汇及主办方、原作者等相关权利人所有。未经许可,禁止进行转载、摘编、复制、裁切、录制等。经许可授权使用,亦须注明来源。欢迎转发、分享。